Alnylam announces proposed offering of $900 million convertible senior notes

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (“alnylam”) (nasdaq: alny), the leading rnai therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to rule 144a under the securities act of 1933, as amended (the “securities act”). in connection with this offering, alnylam expects to gran
ALNY Ratings Summary
ALNY Quant Ranking